An Evaluation of patients' preferences for osteoporosis medications and their attributes: The PREFER-international study

Clinical Therapeutics

Volumn 29, Issue 3, 2007, Pages 488-503

  Duarte, Jesús Walliser ^a   Bolge, Susan C ^b   Sen, Shuvayu S ^c  

^a HOSPITAL ÁNGELES DEL PEDREGAL   (Mexico)

^b Consumer Health Sciences ^*  (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

bisphosphonates; osteoporosis; postmenopause

Indexed keywords

ALENDRONIC ACID; ANALGESIC AGENT; CALCIUM; IBANDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG PREFERENCE; FEMALE; FRACTURE; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; HIP FRACTURE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; RATING SCALE; SPINE FRACTURE; STRUCTURED QUESTIONNAIRE; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CROSS-SECTIONAL STUDIES; EUROPE; FEMALE; FRACTURES, BONE; HUMANS; MEXICO; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT SATISFACTION; QUESTIONNAIRES;

EID: 34250314973     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(07)80087-7     Document Type: Article

References (69)

1. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843 (1994) 1-129
2. Available at:. Osteoporosis in the European Community: Action plan. Accessed. A report of the key next steps towards a Europe free from fragility fractures (February 27, 2006). http://ec.europa.eu/health/ph_projects/2002/promotion/fp_promotion_2002_ a1_04en.pdf
3. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
4. Black D.M., Cummings S.R., Karpf D.B., et al., for the Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348 (1996) 1535-1541
5. Reginster J., Minne H.W., Sorensen O.H., et al., for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11 (2000) 83-91
6. Harris S.T., Watts N.B., Genant H.K., et al., for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA 282 (1999) 1344-1352
7. Reginster J.Y., Adami S., Lakatos P., et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 Year results from the MOBILE study. Ann Rheum Dis 65 (2006) 654-661
8. McCombs J.S., Thiebaud P., McLaughlin-Miley C., and Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48 (2004) 271-287
9. Clowes J.A., Peel N.F., and Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled trial. J Clin Endocrinol Metab 89 (2004) 1117-1123
10. Cramer J.A., Amonkar M.M., Hebborn A., and Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21 (2005) 1453-1460
11. Solomon D.H., Avorn J., Katz J.N., et al. Compliance with osteoporosis medications. Arch Intern Med 165 (2005) 2414-2419
12. Recker R.R., Gallagher R., and MacCosbe P.E. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80 (2005) 856-861
13. Abstract. Negri A.L. Short-term compliance with alendronate 70 mg in patients with osteoporosis: The ECMO trial. Bone 23 Suppl 5 (2003) P487
14. Abstract 1325. Ettinger M.R., Gallagher R., Amonkar M., et al. Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate. Arthritis Rheum 50 Suppl 9 (2004) 5513-5514
15. Caro J.J., Ishak K.J., Huybrechts K.F., et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15 (2004) 1003-1008
16. Huybrechts K.F., Ishak K.J., and Caro J.J. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38 (2006) 922-928
17. Yood R.A., Emani S., Reed J.I., et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14 (2003) 965-968
18. Abstract P391SA. Sebaldt R.J., Shane L.G., Pham B., et al. Longer-term effectiveness outcomes of non-compliance and non-persistence with daily bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist care. Osteoporos Int 15 Suppl 1 (2004) S107
19. van den Boogaard C.H., BreekveldtPostma N.S., Borggreve S.E., et al. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: A database analysis study. Curr Med Res Opin 22 (2006) 1757-1764
20. Laine C., and Davidoff F. Patient-centered medicine. A professional evolution. JAMA 275 (1996) 152-156
21. Kravitz R.L., and Melnikow J. Engaging patients in medical decision making. BMJ 323 (2001) 584-585
22. Bodenheimer T., Lorig K., Holman H., and Grumbach K. Patient self-management of chronic disease in primary care. JAMA 288 (2002) 2469-2475
23. Montgomery A.A., and Fahey T. How do patients' treatment preferences compare with those of clinicians?. Qual Health Care 10 Suppl 1 (2001) i39-i43
24. Sieber W.J., and Kaplan R.M. Informed adherence: The need for shared medical decision making. Control Clin Trials 21 Suppl 5 (2000) 2335-2405
25. Emkey R., Koltun W., Beusterien K., et al. Patient preference for oncemonthly ibandronate versus once weekly alendronate in a randomized, open-label, cross-over trial: The Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21 (2005) 1895-1903
26. Kanis J.A., Oden A., Johnell O., et al. Uncertain future of trials in osteoporosis. Osteoporos Int 13 (2002) 443-449
27. Weiss T.W., Gold D.T., Silverman S.L., and McHorney C.A. An evaluation of patient preferences for osteoporosis medication attributes: Results from the PREFER-US study. Curr Med Res Opin 22 (2006) 949-960
28. Caro G., Caro J.J., O'Brien J.A., et al. Migraine therapy: Development and testing of a patient preference ques tionnaire. Headache 38 (1998) 602-607
29. Unson C.G., Siccion E., Gaztambide J., et al. Nonadherence and osteoporosis treatment preferences of older women: A qualitative study. J Womens Health (Larchmt) 12 (2003) 1037-1045
30. Atkinson M.J., Sinha A., Hass S.L., et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2 (2004) 12
31. Atkinson M.J., Stewart W.C., Fain J.M., et al. A new measure of patient satisfaction with ocular hypotensive medications: The Treatment Satisfaction Survey for Intraocular Pressure (TSS-IOP). Health Qual Life Outcomes 1 (2003) 67
32. Woodcock A., and Bradley C. Validation of the HIV treatment satisfaction questionnaire (HIVTSQ). Qual Life Res 10 (2001) 517-531
33. Green J., Kleinman L., Ciesla G., et al. Subcutaneous injection survey: Psychometric evaluation of a treat ment satisfaction instrument associated with a novel HIV medication. HIV Clin Trials 3 (2002) 387-395
34. Campbell J.L., Kiebert G.M., and Partridge M.R. Development of the satisfaction with inhaled asthma treatment questionnaire. Eur Respir J 22 (2003) 127-134
35. Coyne K.S., Wiklund I., Schmier J., et al. Development and validation of a disease-specific treatment satis faction questionnaire for gastrooesophageal reflux disease. Aliment Pharmacol Ther 18 (2003) 907-915
36. Aristides M., Weston A.R., FitzGerald P., et al. Patient preference and willingness-to-pay for Humalog Mix25 relative to Humulin 30/70: A multicountry application of a discrete choice experiment. Value Health 7 (2004) 442-454
37. Rubin R.R., and Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies [published correction appears in Diabetes Care. 2004;27:3032]. Diabetes Care 27 (2004) 2495-2497
38. Lambert N., Rowe G., Bowling A., et al. Reasons underpinning patients' preferences for various angina treatments. Health Expect 7 (2004) 246-256
39. Fraenkel L., Bogardus Jr. S.T., Concato J., and Wittink D.R. Treatment options in knee osteoarthritis: The patient's perspective. Arch Intern Med 164 (2004) 1299-1304
40. Poster presented at. Schnitzer T.J., Stephenson J.J., Chen Y.T., et al. Systematic review of ibandronate for postmenopausal osteo porosis. Florence, Italy. P0S1. ISPOR 8th Annual European Congress (November 6-8, 2005)
41. Karpf D.B., Shapiro D.R., Seeman E., et al., for the Alendronate Osteoporosis Treatment Study Groups. Prevention of nonvertebral fractures by alendronate. A meta-analysis. JAMA 277 (1997) 1159-1164
42. Wittenberg E., Halpern E., Divi N., et al. The effect of age, race and gender on preference scores for hypothetical health states. Qual Life Res 15 (2006) 645-653
43. Schunemann H.J., Griffith L., Stubbing D., et al. A clinical trial to evaluate the measurement proper ties of 2 direct preference instruments administered with and without hypothetical marker states. Med Decis Making 23 (2003) 140-149
44. Motohiro A., Hirota N., Komatsu H., Yanai N., and for the National Chest Hospital Study Group for Lung Cancer. Japanese doctors' preferred treatment choices for their hypothetical non-small cell lung cancer: How they would wish to be treated. Lung Cancer 11 (1994) 43-50
45. Hanson-Divers C., Jackson S.E., Lue T.F., et al. Health outcomes variables important to patients in the treat ment of erectile dysfunction. J Urol 159 (1998) 1541-1547
46. Kendler D., Kung A.W., Fuleihan G.-H., et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48 (2004) 243-251
47. Simon J.A., Lewiecki E.M., Smith M.E., et al. Patient preference for onceweekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, open-label, crossover study. Clin Ther 24 (2002) 1871-1886
48. Abstract M351. Bracco O.L., Lazaretti-Castro M., Russo L.A., et al. Clinical reasons for prescribing raloxifene or alendro nate in Brazil. J Bone Miner Res 18 Suppl 2 (2003) S379
49. Miller N.H. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 102 (1997) 43-49
50. Osterberg L., and Blaschke T. Adherence to medication. N Engl J Med 353 (2005) 487-497
51. Bowling A., and Ebrahim S. Measuring patients' preferences for treatment and perceptions of risk. Qual Health Care 10 Suppl 1 (2001) i2-i8
52. Rosenstock I.M. The health belief model and nutrition education. J Can Diet Assoc 43 (1982) 184-192
53. Cummings K.M., Jette A.M., and Rosenstock I.M. Construct validation of the health belief model. Health Educ Monogr 6 (1978) 394-405
54. Rosenstock I.M., Strecher V.J., and Becker M.H. Social learning theory and the Health Belief Model. Health Educ Q 15 (1988) 175-183
55. Abstract SA364. Zhang Q., Sautner Z., and Sen S.S. Real-life persistency with Fosamax once weekly, Actonel once weekly, and Boniva once monthly among postmenopausal women in the USA. J Bone Miner Res 21 Suppl 1 (2006) S182
56. Gold D.T., Safi W., and Trinh H. Patient preference and adherence: Comparative US studies between two bisphos phonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 22 (2006) 2383-2391
57. Heiat A., Gross C.P., and Krumholz H.M. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 162 (2002) 1682-1688
58. Murthy V.H., Krumholz H.M., and Gross C.P. Participation in cancer clinical trials: Race-, sex-, and age-based disparities. JAMA 291 (2004) 2720-2726
59. Say R.E., and Thomson R. The importance of patient preferences in treatment decisions-challenges for doctors. BMJ 327 (2003) 542-545
60. Jahng K.H., Martin L.R., Golin C.E., and DiMatteo M.R. Preferences for medical collaboration: Patient-physician congruence and patient outcomes. Patient Educ Couns 57 (2005) 308-314
61. Robinson A., and Thomson R. Variability in patient preferences for participating in medical decision making: Implication for the use of decision support tools. Qual Health Care 10 Suppl 1 (2001) i34-i38
62. Braddock III C.H., Edwards K.A., Hasenberg N.M., et al. Informed decision making in outpatient practice: Time to get back to basics. JAMA 282 (1999) 2313-2320
63. Barry M.J. Involving patients in medical decisions: How can physicians do better?. JAMA 282 (1999) 2356-2357
64. Benbassat J., Pilpel D., and Tidhar M. Patients' preferences for participation in clinical decision making: A review of published surveys. Behav Med 24 (1998) 81-88
65. Deber R.B., Kraetschmer N., and Irvine J. What role do patients wish to play in treatment decision making?. Arch Intern Med 156 (1996) 1414-1420
66. Kassirer J.P. Incorporating patients' preferences into medical decisions. N Engl J Med 330 (1994) 1895-1896
67. Woolf S.H., Chan E.C., Harris R., et al. Promoting informed choice: Transforming health care to dispense knowledge for decision making. Ann Intern Med 143 (2005) 293-300
68. Johnell O., Kanis J., and Gullberg G. Mortality, morbidity, and assessment of fracture risk in male osteo porosis. Calcif Tissue Int 69 (2001) 182-184
69. Borgstrom F., Johnell O., Jonsson B., et al. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 34 (2004) 1064-1071